BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawazoe T, Taniguchi K. The Sprouty/Spred family as tumor suppressors: Coming of age. Cancer Sci 2019;110:1525-35. [PMID: 30874331 DOI: 10.1111/cas.13999] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Endo T. Dominant-negative antagonists of the Ras-ERK pathway: DA-Raf and its related proteins generated by alternative splicing of Raf. Exp Cell Res 2020;387:111775. [PMID: 31843497 DOI: 10.1016/j.yexcr.2019.111775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers (Basel) 2021;13:5059. [PMID: 34680208 DOI: 10.3390/cancers13205059] [Reference Citation Analysis]
3 Locatelli C, Lemonidis K, Salaun C, Tomkinson NCO, Chamberlain LH. Identification of key features required for efficient S-acylation and plasma membrane targeting of sprouty-2. J Cell Sci 2020;133:jcs249664. [PMID: 33037124 DOI: 10.1242/jcs.249664] [Reference Citation Analysis]
4 Wen X, Zhang H, Xiang B, Zhang W, Gong F, Li S, Chen H, Luo X, Deng J, You Y, Hu Z, Jiang C. Hyperoxia-induced miR-342-5p down-regulation exacerbates neonatal bronchopulmonary dysplasia via the Raf1 regulator Spred3. Br J Pharmacol 2021;178:2266-83. [PMID: 33434946 DOI: 10.1111/bph.15371] [Reference Citation Analysis]
5 Ornitz DM, Itoh N. New developments in the biology of fibroblast growth factors. WIREs Mech Dis 2022;:e1549. [PMID: 35142107 DOI: 10.1002/wsbm.1549] [Reference Citation Analysis]
6 Safa A, Abak A, Shoorei H, Taheri M, Ghafouri-Fard S. MicroRNAs as regulators of ERK/MAPK pathway: A comprehensive review. Biomed Pharmacother 2020;132:110853. [PMID: 33068932 DOI: 10.1016/j.biopha.2020.110853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Jafarzadeh A, Paknahad MH, Nemati M, Jafarzadeh S, Mahjoubin-Tehran M, Rajabi A, Shojaie L, Mirzaei H. Dysregulated expression and functions of microRNA-330 in cancers: A potential therapeutic target. Biomed Pharmacother 2021;146:112600. [PMID: 34968919 DOI: 10.1016/j.biopha.2021.112600] [Reference Citation Analysis]
8 Vafeiadou V, Hany D, Picard D. Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer. Cancers (Basel) 2022;14:954. [PMID: 35205702 DOI: 10.3390/cancers14040954] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Motta M, Fasano G, Gredy S, Brinkmann J, Bonnard AA, Simsek-Kiper PO, Gulec EY, Essaddam L, Utine GE, Guarnetti Prandi I, Venditti M, Pantaleoni F, Radio FC, Ciolfi A, Petrini S, Consoli F, Vignal C, Hepbasli D, Ullrich M, de Boer E, Vissers LELM, Gritli S, Rossi C, De Luca A, Ben Becher S, Gelb BD, Dallapiccola B, Lauri A, Chillemi G, Schuh K, Cavé H, Zenker M, Tartaglia M. SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype. Am J Hum Genet 2021;108:2112-29. [PMID: 34626534 DOI: 10.1016/j.ajhg.2021.09.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Tan W, Lin Z, Chen X, Li W, Zhu S, Wei Y, Huo L, Chen Y, Shang C. miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Ann Transl Med 2021;9:38. [PMID: 33553331 DOI: 10.21037/atm-20-2081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Avagliano A, Fiume G, Ruocco MR, Martucci N, Vecchio E, Insabato L, Russo D, Accurso A, Masone S, Montagnani S, Arcucci A. Influence of Fibroblasts on Mammary Gland Development, Breast Cancer Microenvironment Remodeling, and Cancer Cell Dissemination. Cancers (Basel) 2020;12:E1697. [PMID: 32604738 DOI: 10.3390/cancers12061697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zhao G, Pan AY, Feng Y, Rasko JE, Bailey CG, Lovicu FJ. Sprouty and Spred temporally regulate ERK1/2-signaling to suppress TGFβ-induced lens EMT. Experimental Eye Research 2022. [DOI: 10.1016/j.exer.2022.109070] [Reference Citation Analysis]
13 Lorenzo C, McCormick F. SPRED proteins and their roles in signal transduction, development, and malignancy. Genes Dev 2020;34:1410-21. [PMID: 33872193 DOI: 10.1101/gad.341222.120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Georgescu MM. Multi-Platform Classification of IDH-Wild-Type Glioblastoma Based on ERK/MAPK Pathway: Diagnostic, Prognostic and Therapeutic Implications. Cancers (Basel) 2021;13:4532. [PMID: 34572759 DOI: 10.3390/cancers13184532] [Reference Citation Analysis]
15 Lai X, Zhou J, Wessely A, Heppt M, Maier A, Berking C, Vera J, Zhang L. A disease network-based deep learning approach for characterizing melanoma. Int J Cancer 2021. [PMID: 34716589 DOI: 10.1002/ijc.33860] [Reference Citation Analysis]
16 Reischmann N, Andrieux G, Griffin R, Reinheckel T, Boerries M, Brummer T. BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation. Oncogene 2020;39:6053-70. [PMID: 32792685 DOI: 10.1038/s41388-020-01414-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Gong J, Yan Z, Liu Q. Progress in experimental research on SPRED protein family. J Int Med Res 2020;48:300060520929170. [PMID: 32851895 DOI: 10.1177/0300060520929170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Su N, Wang Y, Lu X, Xu W, Wang H, Mo W, Pang H, Tang R, Li S, Yan X, Li Y, Zhang R. Methylation of SPRED1: A New Target in Acute Myeloid Leukemia. Front Oncol 2022;12:854192. [PMID: 35359401 DOI: 10.3389/fonc.2022.854192] [Reference Citation Analysis]
19 Xie C, Liu S, Wu B, Zhao Y, Chen B, Guo J, Qiu S, Cao YM. miR-19 Promotes Cell Proliferation, Invasion, Migration, and EMT by Inhibiting SPRED2-mediated Autophagy in Osteosarcoma Cells. Cell Transplant 2020;29:963689720962460. [PMID: 33023313 DOI: 10.1177/0963689720962460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Niogret C, Birchmeier W, Guarda G. SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling. Front Immunol 2019;10:2468. [PMID: 31708921 DOI: 10.3389/fimmu.2019.02468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Wang X, Lu W, Liu B, Xu Y. Thrombin aggravates hypoxia/reoxygenation injury of astrocytes by activating the autophagy pathway mediated by SPRED2. Exp Ther Med 2021;22:1107. [PMID: 34504561 DOI: 10.3892/etm.2021.10541] [Reference Citation Analysis]
22 Kawazoe T, Taniguchi K. The Sprouty/Spred family as tumor suppressors: Coming of age. Cancer Sci 2019;110:1525-35. [PMID: 30874331 DOI: 10.1111/cas.13999] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
23 Qiao J, Liang C, Zhao D, Nguyen LXT, Chen F, Suo S, Hoang DH, Pellicano F, Rodriguez IR, Elhajmoussa Y, Ghoda L, Yoshimura A, Stein AS, Ali H, Koller P, Perrotti D, Copland M, Han A, Zhang BA, Marcucci G. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. Leukemia 2021. [PMID: 34564700 DOI: 10.1038/s41375-021-01423-x] [Reference Citation Analysis]